Table 2.

Characteristics of stage II–III patients

	CIMP positive (n=64)	CIMP negative (n=132)	p
Age, mean (SD)	73.7 (9.6)	69.7 (11.8)	0.02
Gender, n (%)
Male	27 (42.9)	142 (65.4)	0.003
Female	36 (57.1)	71 (34.6)
TNM stage, n (%)
II	37 (57.8)	71 (53.8)	0.6
III	27 (42.2)	61 (46.2)
MMR deficient, n (%)
Yes	15 (23.4)	3 (2.3)	0.0001
No	49 (76.6)	129 (97.7)
BRAF mutation, n (%)
Yes	13 (20.3)	1 (0.8)	0.0001
No	51 (79.7)	131 (99.2)
Chemotherapy, n (%)
Yes	26 (40.6)	75 (56.8)	0.03
No	38 (69.4)	57 (43.2)
Disease-free survival, n (%)
Yes	36 (56.3)	70 (53.0)	0.7
No	28 (43.8)	62 (47.0)

Disease free survival is the proportion of survivors at the end of follow-up.